Literature DB >> 16939381

Emerging drugs for Parkinson's disease.

John C Morgan1, Kapil D Sethi.   

Abstract

Parkinson's disease (PD) afflicts millions of people worldwide. There are numerous drugs available for PD; however, levodopa remains the gold standard of pharmacotherapy to which all other therapies are compared. Levodopa is quite effective for many motor symptoms (bradykinesia, tremor, rigidity) of PD; however, non-levodopa-responsive motor symptoms (postural instability) and nonmotor symptoms are frequently the most troublesome in middle and later stages of disease. Although motor symptoms remain an important focus for emerging drugs, current research is largely geared to identify and develop disease-slowing therapies. Another important area of focus has become treatment of the nonmotor symptoms of PD (especially depression and dementia). This review discusses emerging drugs in the management of the motor and nonmotor symptoms of PD and drugs under study as disease-slowing/neuroprotective agents.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16939381     DOI: 10.1517/14728214.11.3.403

Source DB:  PubMed          Journal:  Expert Opin Emerg Drugs        ISSN: 1472-8214            Impact factor:   4.191


  7 in total

1.  Effect of opicapone and entacapone upon levodopa pharmacokinetics during three daily levodopa administrations.

Authors:  José-Francisco Rocha; Amílcar Falcão; Ana Santos; Roberto Pinto; Nelson Lopes; Teresa Nunes; Lyndon C Wright; Manuel Vaz-da-Silva; Patrício Soares-da-Silva
Journal:  Eur J Clin Pharmacol       Date:  2014-06-14       Impact factor: 2.953

2.  Effect of opicapone multiple-dose regimens on levodopa pharmacokinetics.

Authors:  José-Francisco Rocha; Éric Sicard; Nicolas Fauchoux; Amílcar Falcão; Ana Santos; Ana I Loureiro; Roberto Pinto; Maria João Bonifácio; Teresa Nunes; Luís Almeida; Patrício Soares-da-Silva
Journal:  Br J Clin Pharmacol       Date:  2016-12-02       Impact factor: 4.335

3.  Expression of catechol-O-methyltransferase in the brain and periphery of normal and MPTP-treated common marmosets.

Authors:  Bai-Yun Zeng; Robert H Balfour; Mike J Jackson; Sarah Rose; Peter Jenner
Journal:  J Neural Transm (Vienna)       Date:  2009-09-22       Impact factor: 3.575

4.  Pharmacokinetics, pharmacodynamics and tolerability of opicapone, a novel catechol-O-methyltransferase inhibitor, in healthy subjects: prediction of slow enzyme-inhibitor complex dissociation of a short-living and very long-acting inhibitor.

Authors:  Luis Almeida; José Francisco Rocha; Amílcar Falcão; P Nuno Palma; Ana I Loureiro; Roberto Pinto; Maria João Bonifácio; Lyndon C Wright; Teresa Nunes; Patrício Soares-da-Silva
Journal:  Clin Pharmacokinet       Date:  2013-02       Impact factor: 6.447

5.  Opicapone: a short lived and very long acting novel catechol-O-methyltransferase inhibitor following multiple dose administration in healthy subjects.

Authors:  José Francisco Rocha; Luis Almeida; Amílcar Falcão; P Nuno Palma; Ana I Loureiro; Roberto Pinto; Maria João Bonifácio; Lyndon C Wright; Teresa Nunes; Patrício Soares-da-Silva
Journal:  Br J Clin Pharmacol       Date:  2013-11       Impact factor: 4.335

6.  Dual beneficial effects of (-)-epigallocatechin-3-gallate on levodopa methylation and hippocampal neurodegeneration: in vitro and in vivo studies.

Authors:  Ki Sung Kang; Yujing Wen; Noriko Yamabe; Masayuki Fukui; Stephanie C Bishop; Bao Ting Zhu
Journal:  PLoS One       Date:  2010-08-05       Impact factor: 3.240

Review 7.  Neuroprotective Properties of Green Tea (Camellia sinensis) in Parkinson's Disease: A Review.

Authors:  Dicson Sheeja Malar; Mani Iyer Prasanth; James Michael Brimson; Rajasekharan Sharika; Bhagavathi Sundaram Sivamaruthi; Chaiyavat Chaiyasut; Tewin Tencomnao
Journal:  Molecules       Date:  2020-08-27       Impact factor: 4.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.